Loss of oxybate franchise revenue
The company states that inability to maintain oxybate revenues would materially hurt business and growth prospects.
- Scope
- Xywav and Xyrem
- Materiality
- high
Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a biopharmaceutical company focused on medicines for serious diseases, with a portfolio centered on neuroscience and oncology. It commercializes products such as Xywav, Epidiolex/Epidyolex, Zepzelca, Rylaze, Vyxeos, Defitelio, Ziihera and Modeyso, while also advancing a pipeline of product candidates and pursuing acquisitions and in-licensing to expand its portfolio.
−9,1 %
−8,3 %
+4,9 %
1.86
1.67
| % | |
|---|---|
| Neuroscience medicines | 68% Commercial products for sleep disorders and epilepsy, including oxybate therapies and cannabidiol-based treatment. |
| Oncology medicines | 26% Hospital and specialty oncology products used in hematology and solid tumor settings. |
| Royalties and contract revenues | 6% Royalty income and other contract-based revenues tied to partnered or licensed assets. |
Jazz sells primarily to specialty pharmacies, specialty distributors, wholesalers, hospitals and institutional...
- Specialty pharmaciesprimary
Buy Xywav, Xyrem, Epidiolex and Modeyso for controlled dispensing and direct patient shipment.
- Hospitals and oncology institutionsprimary
Buy Defitelio, Vyxeos, Zepzelca, Rylaze and Ziihera for inpatient and outpatient cancer care.
- Wholesalers and specialty distributorsprimary
Purchase and distribute products across the U.S. and international markets to maintain access.
- Patients via certified channelssecondary
End users of oxybate and epilepsy therapies, reached through specialty pharmacy and reimbursement support.
- International healthcare systemssecondary
Buy through local distributors, named-patient programs and market authorization pathways in Europe and Canada.
Jazz operates directly in the U.S., Europe, Australia and Canada, and uses distributors in other key global markets...
- •U.S. is the main commercial market for most products and patient services
- •Direct operations in Europe, Australia and Canada support local commercialization
- •International distributors extend reach in markets where Jazz does not sell directly
- •U.K., Ireland and EU are major operating locations for non-U.S. staff
- •Europe and Canada are especially important for Defitelio, Vyxeos and Epidyolex
Jazz is prioritizing commercial execution in neuroscience and oncology while expanding its pipeline through internal...
01
Commercialize and expand current marketed productsshort-term
Existing products fund the business and support near-term growth while the company builds its pipeline.
02
Advance R&D and clinical developmentmedium-term
Pipeline success is needed to replace mature assets and create longer-duration growth drivers.
03
Acquire or in-license differentiated assetsmedium-term
External deal-making is a core path to portfolio expansion and diversification.
Jazz is exposed to concentration risk in its oxybate franchise and to execution risk around launching and scaling newer...
Government investigations and drug pricing scrutiny
Oversight can create legal expense, reputational damage and reduced market acceptance.
- Scope
- U.S. pricing and compliance practices
- Materiality
- high
Clinical development and regulatory approval failure
Pipeline value depends on successful trials and timely approvals for new products.
- Scope
- Oncology and neuroscience candidates
- Materiality
- high
Cybersecurity and IT incidents
A breach or outage could interrupt operations, expose data and weaken internal controls.
- Scope
- Global commercial and R&D systems
- Materiality
- medium
Acquisition and integration risk
Deal-making is central to strategy, but integration issues can impair returns and liquidity.
- Scope
- Product acquisitions and in-licensing, including Chimerix
- Materiality
- medium
Revenue deductions and reserves
Can materially change quarterly product sales and margins
Point-in-time revenue recognition
Can shift revenue between periods based on shipment and patient dispensing timing
Goodwill impairment
A write-down would reduce earnings and signal weaker acquisition value
Acquisition-related contingent consideration and royalties
Affects liabilities, future cash outflows and earnings presentation
Maze Therapeutics, Inc.
MAZE · Biological Products, (No Diagnostic Substances)
LENZ Therapeutics, Inc.
LENZ · Biological Products, (No Diagnostic Substances)
LENZ Therapeutics is a U.S.-based pre-commercial biopharmaceutical company focused on developing and commercializing VIZZ, an aceclidine-based eye drop for presbyopia.
IONIS PHARMACEUTICALS INC
IONS · Pharmaceutical Preparations
Ionis Pharmaceuticals is a U.S.-based biotechnology company focused on RNA-targeted medicines, using antisense chemistry to discover and develop therapies for serious diseases.
MADRIGAL PHARMACEUTICALS, INC.
MDGL · Pharmaceutical Preparations
Madrigal Pharmaceuticals is a U.S.-based commercial-stage biopharmaceutical company focused on developing and selling therapies for metabolic dysfunction-associated steatohepatitis (MASH).
Cinclus Pharma Holding
CINPHA.ST · Health Care
Cinclus Pharma Holding AB is a Swedish pharmaceutical company focused on developing and commercializing innovative treatments for gastroesophageal reflux disease (GERD).
RHYTHM PHARMACEUTICALS, INC.
RYTM · Pharmaceutical Preparations
Rhythm Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for rare genetic disorders of obesity and related metabolic diseases.
: 28.4.2026